- Home
- PDD vs GILD Comparison
PDD vs GILD Comparison
Compare PDD & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDD
- GILD
- Stock Information
- Founded
- PDD 2015
- GILD 1987
- Country
- PDD Ireland
- GILD United States
- Employees
- PDD N/A
- GILD N/A
- Industry
- PDD Business Services
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PDD Consumer Discretionary
- GILD Health Care
- Exchange
- PDD Nasdaq
- GILD Nasdaq
- Market Cap
- PDD 162.9B
- GILD 138.2B
- IPO Year
- PDD 2018
- GILD 1992
- Fundamental
- Price
- PDD $119.07
- GILD $111.89
- Analyst Decision
- PDD Buy
- GILD Buy
- Analyst Count
- PDD 12
- GILD 27
- Target Price
- PDD $155.08
- GILD $105.32
- AVG Volume (30 Days)
- PDD 9.0M
- GILD 9.9M
- Earning Date
- PDD 03-20-2025
- GILD 04-24-2025
- Dividend Yield
- PDD N/A
- GILD 2.82%
- EPS Growth
- PDD 84.70
- GILD N/A
- EPS
- PDD 10.41
- GILD 0.38
- Revenue
- PDD $53,956,802,414.00
- GILD $28,754,000,000.00
- Revenue This Year
- PDD $27.29
- GILD $1.77
- Revenue Next Year
- PDD $19.80
- GILD $3.52
- P/E Ratio
- PDD $11.44
- GILD $294.45
- Revenue Growth
- PDD 59.04
- GILD 6.04
- 52 Week Low
- PDD $88.01
- GILD $62.07
- 52 Week High
- PDD $164.69
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- PDD 47.11
- GILD 57.09
- Support Level
- PDD $117.29
- GILD $109.60
- Resistance Level
- PDD $125.40
- GILD $112.86
- Average True Range (ATR)
- PDD 4.82
- GILD 2.38
- MACD
- PDD -0.99
- GILD -0.21
- Stochastic Oscillator
- PDD 12.51
- GILD 83.03
About PDD PDD Holdings Inc.
PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. PDD aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from the increased productivity and new opportunities. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).